Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: Effect of variation in treatment schedule with PEG-rHuMGDF

Stem Cells

Volumn 21, Issue 1, 2003, Pages 79-89

  Farese, Ann M ^a   MacVittie, Thomas J ^a   Roskos, Lorin ^b   Stead, Richard B ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

Bone marrow transplant; Hematopoietic; Nonhuman primate; PEG rHuMGDF; Platelet

Indexed keywords

CYTOKINE; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; MYELOABLATIVE AGENT; PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE GRAFT; BONE MARROW TRANSPLANTATION; CLONOGENESIS; CLONOGENIC ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MECHANISM; HEMATOPOIESIS; MALE; MATHEMATICAL MODEL; MONONUCLEAR CELL; NONHUMAN; PHARMACODYNAMICS; RHESUS MONKEY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ANIMALIA; MACACA MULATTA; PRIMATES;

EID: 0037237460     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.21-1-79     Document Type: Article

References (73)

1. Sheridan WP, Begley G, Juttner CA et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992;339:640-644.
2. To LB, Dyson PG, Branford AL. Peripheral blood stem cells collected in very early remission produce rapid and sustained autologous haemopoietic reconstitution in acute non-lymphoblastic leukemia. Bone Marrow Transplant 1987;2:103-108.
3. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993;11:369-374.
4. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031-2035.
5. Appelbaum FR, Herzig GP, Ziegler JL et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978;52:85-95.
6. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-284.
7. Hill RS, Mazza P, Amos D. Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation. Bone Marrow Transplant 1989;4:69-74.
8. Shpall EJ, LeMaistre CF, Holland K et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 1997;90:4313-4320.
9. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-1143.
10. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-838.
11. Nienhuis AW, Donahue RE, Karlsson S et al. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest 1987;80:573-577.
12. Monroy RL, Skelly RR, MacVittie TJ et al. The effect of recombinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow. Blood 1987;70:1696-1699.
13. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-1778.
14. Sheridan WP, Morstyn G, Wolf M et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-895.
15. Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation [Published erratum in Lancet 1994 26;343:804]. Lancet 1994;343:696-700.
16. Taylor KM, Jagannath S, Spitzer G et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989;7:1791-1799.
17. Molineux G, Hartley C, McElroy P et al. An analysis of the effects of combined treatment with RmGM-CSF and PEG-RHuMGDF in murine bone marrow transplant recipients. STEM CELLS 1997;15:43-49.
18. Molineux G, Hartley C, McElroy P et al. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 1996;88:1509-1514.
19. Kabaya K, Shibuya K, Torii Y et al. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice. Bone Marrow Transplant 1996;18:1035-1041.
20. Fibbe WE, Heemskerk DP, Laterveer L et al. Accelerated reconsitufion of platelets and erythrocytes after syngenic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995;86:3308-3313.
21. Neelis KJ, Dubbelman YD, Wognum AW et al. Lack of efficacy of thrombopoietin and granulocyte colony- stimulating factor after high dose total-body irradiation and autologous stem cell or bone marrow transplantation in rhesus monkeys. Exp Hematol 1997;25:1094-1103.
22. Farese AM, Stead RB, Roskos L et al. Hematopoietic recovery following autologous bone marrow transplantation: effect of pretreatment and/or therapeutic administration of PEG-rHuMGDF. Blood 1996;88:600a.
23. Nash RA, Takatu A, Feng Z et al. Effect of C-Mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization. Biol Blood Marrow Transplant 2002;8:360-367.
24. Neelis KJ, Hartong SC, Egeland T et al. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood 1997;90:2565-2573.
25. Neelis KJ, Dubbelman YD, Qingliang L et al. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol 1997;25:1084-1093.
26. Farese AM, Hunt P, Grab LB et al. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996;97:2145-2151.
27. Kaushansky K, Broudy VC, Grossmann A et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995;96:1683-1687.
28. Ulich TR, del Castillo JD, Senaldi G et al. PEG-RHuMGDF promotes multilineage hematopoietic recovery in myelosuppressed mice. Exp Hematol 1999;27:1776-1781.
29. Ulich TR, del Castillo J, Yin S et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995;86:971-976.
30. Akahori H, Shibuya A, Obuchi M et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 1996;94:722-728.
31. Thomas GR, Thibodeaux H, Erret CJ et al. In vivo biological effects of various forms of thrombopoietin in a murine model of transient thrombocytopenia. STEM CELLS 1996;14(suppl 1):246-255.
32. Shibuya K, Akahori H, Takahashi K et al. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood 1998;91:37-45.
33. Akahori H, Shibuya A, Ozai M et al. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. STEM CELLS 1996;14:678-689.
34. Farese A, MacVittie TJ, Lind LB et al. The combined administration of daniplestim and MpL ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression. STEM CELLS 1998;16(suppl 2):143-154.
35. Andrews RG, Winkler A, Myerson D et al. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons. STEM CELLS 1996;14:661-677.
36. Farese AM, Smith WG, Giri JG et al. Promegapoietin-la, an engineered chimeric IL-3 and Mpl-L receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedules following radiation-induced myelosuppression in nonhuman primates. STEM CELLS 2001;19:329-338.
37. Basser RL, Rasko JE, Clarke K et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-RHuMGDF) in patients with advanced cancer. Lancet 1996;348:1279-1281.
38. Fanucchi M, Glaspy J, Crawford J et al. Effects of polyethylene glycol -conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404-409.
39. Basser RL, Rasko JEJ, Clarke K et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997;89:3118-3128.
40. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic malignancy. Ann Intern Med 2000;132:364-368.
41. O'Malley CJ, Rasko JE, Basser RL et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996;88:3288-3298.
42. Schiffer CA, Miller K, Larson RA et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000;95:2530-2534.
43. Archimbaud E, Ottmann OG, Liu-Yin JA et al. A randomized, double-blinded, placebo controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-RHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999;94:3694-3701.
44. Glaspy J, Vredenburgh JJ, Demetri GD et al. Effect of pegylated recombinant megakaryocyte growth and development factor (PEG-RHuMGDF) before high dose chemotherapy with peripheral blood progenitor cell (PBPC) support. Blood 1997;90:580a.
45. Vadhan-Raj S, Patel S, Broxmeyer H et al. Schedule effect of recombinant human thrombopoietin (rhTPO) in attenuating thrombocytopenia in patients receiving dose intensive chemotherapy with adriamycin (A) and ifosfamide (I). Blood 2000;96:455a.
46. Nash RA, Kurzrock R, DiPersio J et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000;6:25-34.
47. Fields KK, Crump M, Bence-Bruckler I et al. Use of PEG-RHuMGDF in platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant 2000;26:1083-1088.
48. Bolwell B, Vredenburgh J, Overmoyer B et al. Phase I study of pegylated recombinant human megkaryocyte growth and development factor (PEG-RHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000;26:141-145.
49. Wolff SN, Herzig R, Lynch J et al. Recombinant human thrombopoietin (RhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant 2001;27:261-268.
50. Roskos L, Stead R, Harker L et al. A cytokinetic model of platelet (PLT) production and destruction following administration of PEG-rHuMGDF. Blood 1997;90:171a.
51. Harker LA, Roskos LK, Marzec UM et al. Effect of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000;95:2514-2522.
52. Mackarehtschian K, Hardin JD, Moore KA et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995;3:147-161.
53. Farese AM, Casey DB, Vigneulle RM et al. A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. STEM CELLS 2001;19:514-521.
54. Beveridge R, Schuster M, Waller E et al. Randomized, double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients (Pts) following autologous bone marrow transplantation (ABMT). Blood 1997;90:580a.
55. Vadhan-Raj S, Patel S, Broxmeyer H et al. Schedule-dependent reduction in thrombocytopenia by recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I). Proc Am Soc Clin Oncol 1999;18:52a.
56. Mouthon MA, Van der Meeren A, Gaugler MH et al. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Int J Radiat Oncol Biol Phys 1999;43:867-875.
57. Pestina TI, Cleveland JL, Yang C et al. mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. Blood 2001;98:2084-2090.
58. Wagemaker G, Neelis KJ, Hartong SC et al. The efficacy of recombinant TPO in murine and nonhuman primate models for myelosuppression and stem cell transplantation. STEM CELLS 1998;16(suppl 2):127-141.
59. Borge OJ, Ramsfjell V, Veiby OP et al. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro. Blood 1996;88:2859-2870.
60. - bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. Blood 1997;90:2282-2292.
61. MacVittie TJ, Farese AM, Grab LB et al. Effect of delayed administration of recombinant human megakaryocyte growth and development factor on hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia. Exp Hematol 1995;23:830a.
62. Ohwada A, Rafii S, Moore MA et al. In vivo adenovirus vector-mediated transfer of the human thrombopoietin cdna maintains platelet levels during radiation- and chemotherapy-induced bone marrow suppression. Blood 1996;88:778.
63. Fox N, Priestley GV, Papayannopoulou T et al. Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest 2002;110:389-394.
64. Nichol JL. Endogenous TPO (ETPO) levels in health and disease: possible clues for therapeutic intervention. STEM CELLS 1998;16(suppl 2):165-175.
65. Fielder PJ, Gurney AL, Stefanich E et al. Regulation of thrombopoietin levels by C-Mpl-mediated binding to platelets. Blood 1996;87:2154-2161.
66. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-2730.
67. Emmons RV, Reid DM, Cohen RL et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-4071.
68. Shimazaki C, Inaba T, Uchiyama H et al. Serum thrombopoietin levels in patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997;19:771-775.
69. Tanum G. The megakaryocyte DNA content and platelet formation after the sublethal whole body irradiation of rats. Blood 1984;63:917-920.
70. Harker LA, Hunt P, Marzec UM et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996;87:1833-1844.
71. Jiang S, Levine JD, Fu Y et al. Cytokine production by primary bone marrow megakaryocytes. Blood 1994;84:4151-4156.
72. Wickenhauser C, Lorenzen J, Thiele J et al. Secretion of cytokines (Interleukins-1, -3, and -6 and granulocyte macrophage colony-stimulating factor) by normal human bone marrow megakaryocytes. Blood 1995;85:685-691.
73. Nagahisa H, Nagata Y, Ohnuki T et al. Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation. Blood 1996;87:1309-1316.